Advertisement
UK markets closed

  • FTSE 100

    8,044.81
    +20.94 (+0.26%)
     

  • FTSE 250

    19,799.72
    +200.33 (+1.02%)
     

  • AIM

    754.87
    +5.69 (+0.76%)
     

  • GBP/EUR

    1.1630
    +0.0041 (+0.36%)
     

  • GBP/USD

    1.2442
    +0.0091 (+0.74%)
     

  • Bitcoin GBP

    53,593.06
    +394.53 (+0.74%)
     

  • CMC Crypto 200

    1,432.95
    +18.19 (+1.29%)
     

  • S&P 500

    5,066.19
    +55.59 (+1.11%)
     

  • DOW

    38,466.93
    +226.95 (+0.59%)
     

  • CRUDE OIL

    82.97
    +1.07 (+1.31%)
     

  • GOLD FUTURES

    2,335.70
    -10.70 (-0.46%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • CAC 40

    8,105.78
    +65.42 (+0.81%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

US and EU Biotech Industry VC Investment Growth Opportunities

ReportLinker
·2-min read

With this research service, the analyst provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment.

New York, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "US and EU Biotech Industry VC Investment Growth Opportunities" - https://www.reportlinker.com/p06149553/?utm_source=GNW
The study also identifies actionable growth opportunities for industry participants to leverage.

Capital flow has grown dramatically in biotech due to emergence of start-ups and small/midsize biotech having advanced techniques involved in next-generation therapies, such as immunotherapies and personalized medicines. In the biopharma sector, companies with platform technology for targeting multiple indications in early clinical and preclinical stages, such as Roviant Sciences, Curevac, and Sana Biotechnology saw the highest investments in 2020.This report reviews the significant drivers that will propel the VC investment in biotech and specifically CGT. It highlights the dynamics of the Chinese investors in the biotech VC landscape.Other discussions on the biotech VC investment trend include:
• The healthcare sector VC landscape in the US and EU from 2018 to 2020.
• Key trends in biopharma VC investment.
• Analysis of global biotech VC deals by modality from 2016 to H1 2021.
• Analysis of global biotech VC deals by therapeutic segment from 2016 to H1 2021.
• Analysis of global biotech VC deals by stage of clinical development from 2016 to H1 2021.
• A snapshot of the VC investment trend in the CGT segment.
• The key companies to watch in the CGT space.
• Key growth opportunities paving the way for future VC investment in the biotech industry.
Author: Surbhi Gupta
Read the full report: https://www.reportlinker.com/p06149553/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001